Peter Lurie

President and Executive Director, Center for Science in the Public Interest

Peter Lurie is president and executive director of the Center for Science in the Public Interest. Previously, Lurie was associate commissioner for public health strategy and analysis at the FDA, working on antimicrobial resistance, drug shortages, agency transparency, caffeinated beverages, arsenic in rice, expanded access to investigational drugs, and prescription drug abuse. Prior to that, he was deputy director of Public Citizen’s Health Research Group, where he addressed drug and device issues, coauthored the organization’s Worst Pills, Best Pills consumer guide to medications, and led efforts to reduce worker exposure to hexavalent chromium and beryllium. As a faculty member at the University of California, San Francisco, and the University of Michigan, he studied needle exchange programs, ethical aspects of mother-to-infant HIV transmission studies, and other HIV policy issues.

Debates Featuring Peter Lurie

Is the FDA Too Cautious?

With Colin Hill, Peter Lurie

June 23, 2023

During the COVID-19 pandemic, the Atlantic criticized the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio ran a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to move safe and effective drugs as quickly as possible to patients who need them, it also needs to maintain the diligence and rigor necessary to prevent…

Is the FDA Too Cautious?

With Colin Hill, Peter Lurie

June 23, 2023

Features

Topics

Upcoming debates

SUPPORT OPEN-MINDED DEBATE

Peter Lurie

Debates Featuring Peter Lurie

Is the FDA Too Cautious?

Is the FDA Too Cautious?

Be Curious. Be Open-Minded. Be Open to Debate.